The burgeoning field of metabolic disease management is witnessing a exciting convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://sociallytraffic.com/story6663155/retatrutide-and-nad-a-integrated-system-to-physiological-condition